Literature DB >> 2846625

Successful treatment with SMS 201-995 of Cushing's syndrome caused by ectopic adrenocorticotropin secretion from a metastatic gastrin-secreting pancreatic islet cell carcinoma.

S W Lamberts1, H W Tilanus, A I Klooswijk, H A Bruining, A J van der Lely, F H de Jong.   

Abstract

Signs and symptoms of Cushing's syndrome developed rapidly after total gastrectomy in a 37-yr-old man with a metastatic gastrin-secreting islet cell carcinoma. Argyrophilic tumor cells in a lymph node removed during operation immunostained for gastrin and ACTH. Treatment for more than 6 months with the somatostatin analog SMS 201-995 (300 micrograms/day) greatly reduced serum gastrin levels and normalized plasma ACTH and cortisol levels and urinary cortisol excretion, and the signs and symptoms of Cushing's syndrome disappeared. The size of the primary tumor in the head of the pancreas, which had grown rapidly before SMS 201-995 therapy, stabilized after 6 months of treatment with the analog. We conclude that SMS 201-995 can reduce ACTH as well as gastrin secretion from islet cell carcinomas as well as control tumor growth.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846625     DOI: 10.1210/jcem-67-5-1080

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

2.  Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis.

Authors:  E Roti; R Minelli; E Gardini; M Salvi; L Bianconi; L Balducci; A Manfredi; L E Braverman
Journal:  J Endocrinol Invest       Date:  1990-01       Impact factor: 4.256

Review 3.  The ectopic ACTH syndrome.

Authors:  Krystallenia I Alexandraki; Ashley B Grossman
Journal:  Rev Endocr Metab Disord       Date:  2010-06       Impact factor: 6.514

4.  Long-term treatment of Nelson's syndrome by octreotide: a case report.

Authors:  L Petrini; M Gasperi; R Pilosu; A Marcello; E Martino
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

5.  Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion.

Authors:  C de Bruin; L J Hofland; L K Nieman; P M van Koetsveld; A M Waaijers; D M Sprij-Mooij; M van Essen; S W J Lamberts; W W de Herder; R A Feelders
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

6.  Ectopic ACTH syndrome caused by pheochromocytoma: computed tomography-guided percutaneous ethanol injection as an alternative treatment.

Authors:  D L Danilovic; R A Brandão Neto; H D'Abronzo; M R Menezes; A M Lucon; B B Mendonca
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

7.  Cushing's syndrome in medullary thyroid carcinoma.

Authors:  A Mure; C Gicquel; N Abdelmoumene; F Tenenbaum; C Francese; J P Travagli; P Gardet; M Schlumberger
Journal:  J Endocrinol Invest       Date:  1995-03       Impact factor: 4.256

Review 8.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

9.  Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.

Authors:  B Ambrosi; D Bochicchio; C Fadin; P Colombo; G Faglia
Journal:  J Endocrinol Invest       Date:  1990-03       Impact factor: 4.256

10.  Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature.

Authors:  Da Zhang; Lin Lu; Hui-Juan Zhu; Yu Xiao; Xian-Lin Han; Shun-Da Du; Hua-Dan Xue; Qing-Xing Liu; Zhao-Hui Zhu; Ming-Ming Hu; Xiao Zhai; Xiao-Ping Xing; Zhao-Lin Lu
Journal:  Int J Endocrinol       Date:  2022-02-28       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.